Thermo Fisher Scientific

Articles

Learn how Gibco™ Rapid Prototyping can help idenitfy the most feasible cell culture media for cGMP scale-up.

Accelerate media development and scale up with Gibco™ Rapid Prototyping (June 2023)

This session will address  ways to help streamline media manufacturing, including rapid, small-scale non-cGMP media prototyping and proprietary media formulation outsourcing options.

Accelerating Cell Culture Media Manufacturing: From Rapid Prototyping Through cGMP (June 2023)

How to achieve robust and consistent high-quality productivity for successful commercial manufacturing is dependent on clearly defining your criteria for successful scale-up. This article explains how using a fully optimized cell culture medium, and identifying it early in the development process, should be part of the criteria as they can avoid time-consuming and costly redevelopment at scale-up.

The Keys to Achieve Success with Commercial AAV Manufacturing Scale-up

This brochure presents Gibco™ products and dedicated support services backed by a robust global manufacturing network to help you scale up your AAV manufacturing workflow with confidence and meet your project goals

Scaling up AAV Production with Thermo Fisher Scientific Gene Therapy Solutions

As processes increase in scale, the greater raw material volumes and stricter quality requirements can make it challenging to deliver an effective and economically feasible product. In this how-to guide, we discuss the common challenges that developers face when moving through process development and outline the essential steps for streamlining scale-up through effective raw material sourcing.

Straight From the Source: Streamlining Scale-up With Quality Raw Materials

Although the potential of gene therapy has been established for decades, it is only in recent years that the industry has seen a major turning point with the first therapies receiving approval in the late 2010s. As the potential of these therapies is realized, the question of the hour is: how do we manufacture AAV gene therapies sustainably in the long term?